The firm initiated coverage of this stock with an outperform rating and a $40 price target.
You are here: Home / This little-known biotech stock developing treatments for blood disorders could jump 80%, BMO says
Market News and Views
The firm initiated coverage of this stock with an outperform rating and a $40 price target.